BLA 761501, held by Biocon Biologics. Pertuzumab.
As of Nov 18, 2026, BLA 761501 (Pebrilzo), held by Biocon Biologics, was first approved by FDA on Nov 12, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pebrilzo420MG/14ML (30MG/ML) · solution;injection | Pertuzumab | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters